Paper Details

  1. Home
  2. Paper Details

A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.

Author: BallalShaila, DarkenPatrick, DorinskyPaul, FergusonGary T, MartinezFernando J, McLarenJulie, RabeKlaus F, ReisnerColin, SinghDave, St RoseEarl, TrivediRoopa, WangChen, WedzichaJadwiga A

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review examines the optimal patient population and benefit:risk ratio of single inhaler triple therapy (ICS/LAMA/LABAs) for chronic obstructive pulmonary disease (COPD).
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND">Single inhaler triple therapies providing an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting &#946;<sub>2</sub>-agonist (ICS/LAMA/LABAs) are an emerging treatment option for chronic obstructive pulmonary disease (COPD). Nevertheless, questions remain...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.rmed.2019.08.010

データ提供：米国国立医学図書館（NLM）

Triple Therapy for COPD: A New Frontier in Respiratory Care

Chronic obstructive pulmonary disease (COPD) is a debilitating lung condition that can feel like navigating a desert of breathlessness and discomfort. This research explores the potential of a [triple therapy] using a [single inhaler] that combines an [inhaled corticosteroid], a [long-acting muscarinic antagonist], and a [long-acting β2-agonist (LABA)] to treat COPD. The study aimed to evaluate the [efficacy and safety] of this novel approach in a [phase III clinical trial] of patients with moderate-to-very severe COPD.

A Multi-faceted Approach to Managing COPD

The study, known as the ETHOS study, is designed to investigate the [optimal patient population] for [triple therapy] and to assess the [benefit-risk ratio] of [inhaled corticosteroid treatment]. The researchers will evaluate the [clinical outcomes] and [adverse events] associated with the triple therapy, comparing its effectiveness to existing treatment options. This research is a crucial step in advancing our understanding of how to best manage COPD and improve the lives of individuals living with this condition.

Exploring New Horizons in COPD Treatment

This research offers a glimpse into the future of [COPD treatment]. The development of [triple therapy] holds the potential to revolutionize [lung care], offering a [more effective] and [well-tolerated] approach for managing this chronic condition. The ETHOS study's findings will be essential in guiding future treatment decisions and shaping the landscape of respiratory care.

Dr.Camel's Conclusion

Just as a camel must adapt to the changing environment of a desert, individuals with COPD often face a constant struggle to breathe comfortably. This research offers a beacon of hope by exploring a new and potentially transformative approach to COPD management. The ETHOS study's findings have the potential to provide greater clarity on the best paths to improving quality of life for those living with COPD.

Date :
  1. Date Completed 2020-08-03
  2. Date Revised 2021-03-17
Further Info :

Pubmed ID

31605923

DOI: Digital Object Identifier

10.1016/j.rmed.2019.08.010

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.